文献速递疼痛医学

生理性ECAP闭环脊髓电刺激治疗慢性疼痛3年神经生理结局

Neurophysiological outcomes that sustained clinically significant improvements over 3 years of physiologic ECAP-controlled closed-loop spinal cord stimulation for the treatment of chronic pain.
PubMed 文献 · Reg Anesth Pain Med · 2025-06-10

EVOKE双盲随机对照试验中41例随机接受闭环脊髓电刺激(CL-SCS)的患者随访36个月,反馈环将诱发的ECAP维持在目标值4µV以内,高于ECAP阈值刺激时间占比>98%,ECAP剂量≥19.3µV,83%患者背部和腿部整体疼痛缓解≥50%,59%缓解≥80%,3至36个月间应答率无显著变化。

要点

  • CL-SCS闭环反馈可将诱发ECAP精准控制在目标值4µV以内。
  • 高于ECAP阈值的刺激时间占比>98%,ECAP剂量≥19.3µV。
  • 83%患者疼痛缓解≥50%,59%缓解≥80%,36个月内持续有效。

核心结论

  • ECAP控制的闭环脊髓电刺激通过生理性坚持高于ECAP阈值的治疗产生疼痛抑制,在36个月随访中带来持久的疼痛强度改善,无治疗效应丧失证据。

研究设计与样本

  • EVOKE双盲随机对照试验队列,41例随机分配至CL-SCS的患者保持原治疗分配并随访至36个月,分析客观神经生理数据包括脊髓激活指标。

主要发现

  • 反馈环性能实现高剂量准确性,在所有时间点将诱发的ECAP维持在系统设定目标ECAP的4µV以内。
  • 高于ECAP阈值的刺激时间百分比>98%,ECAP剂量≥19.3µV。
  • 83%患者获得背部和腿部整体疼痛≥50%缓解,59%获得≥80%缓解。
  • 3个月至36个月随访间应答率持续,≥50%缓解率比较p=0.083,≥80%缓解率比较p=0.405。

关键数值与推荐

  • 反馈环将诱发ECAP维持在目标值4µV以内。
  • 高于ECAP阈值刺激时间占比>98%。
  • ECAP剂量≥19.3µV。
  • 疼痛缓解≥50%患者比例83%,≥80%患者比例59%。

临床怎么用

  • CL-SCS治疗中应利用ECAP反馈确保刺激高于ECAP阈值并维持目标ECAP剂量,以支持疼痛缓解的长期维持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A novel, spinal cord stimulation (SCS) system with a physiologic closed-loop (CL) feedback mechanism controlled by evoked compound action potentials (ECAPs) enables the optimization of physiologic neural dose and the accuracy of the stimulation, not possible with any other commercially available SCS systems. The report of objective spinal cord measurements is essential to increase the transparency and reproducibility of SCS therapy. Here, we report a cohort of the EVOKE double-blind randomized controlled trial treated with CL-SCS for 36 months to evaluate the ECAP dose and accuracy that sustained the durability of clinical improvements. METHODS: 41 patients randomized to CL-SCS remained in their treatment allocation and were followed up through 36 months. Objective neurophysiological data, including measures of spinal cord activation, were analyzed. Pain relief was assessed by determining the proportion of patients with ≥50% and ≥80% reduction in overall back and leg pain. RESULTS: The performance of the feedback loop resulted in high-dose accuracy by keeping the elicited ECAP within 4µV of the target ECAP set on the system across all timepoints. Percent time stimulating above the ECAP threshold was >98%, and the ECAP dose was ≥19.3µV. Most patients obtained ≥50% reduction (83%) and ≥80% reduction (59%) in overall back and leg pain with a sustained response observed in the rates between 3-month and 36-month follow-up (p=0.083 and p=0.405, respectively). CONCLUSION: The results suggest that a physiological adherence to supra-ECAP threshold therapy that generates pain inhibition provided by ECAP-controlled CL-SCS leads to durable improvements in pain intensity with no evidence of loss of therapeutic effect through 36-month follow-up.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Mekhail NA, Levy RM, Deer TR, et al. Neurophysiological outcomes that sustained clinically significant improvements over 3 years of physiologic ECAP-controlled closed-loop spinal cord stimulation for the treatment of chronic pain. Reg Anesth Pain Med. 2025. PMID: 38490687. doi:10.1136/rapm-2024-105370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。